Block (ASX:SQ2) attacked by a short-seller
Nick Sundich, March 24, 2023
Jack Dorsey-led fintech Block (ASX:SQ2) has been attacked by short-seller Hindenburg Research.
Hindenburg has essentially alleged the entire company is a fraud while SQ2 has predictably denied the allegations and threatened legal action, as most companies in this position do.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
Hindenburg’s allegations
Hindenburg Research claimed to have conducted a 2-year investigation into the company, interviewing former employees and industry experts, reviewing regulatory and litigation records and financial modelling.
Among its allegations were that it overstated its user counts, understated customer acquisition costs and failed to take action against criminal activity being done using the app.
The report led to the company’s shares falling over 16% this morning. It debuted on the ASX in February 2022 after acquiring Afterpay.

Block (ASX:SQ2) share price chart, log scale (Source: TradingView)
Block response
The company released a short statement on its website in which it denied the allegations and said it would explore legal action against Hindenburg.
‘We are a highly regulated public company with regular disclosures, and are confident in our products, reporting, compliance programs, and controls,’ it said.
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Trump vs. Jerome Powell: What Happens to the Market If Powell Is Fired?
The relationship between President Donald Trump and Federal Reserve Chair Jerome Powell has often been tumultuous, particularly around decisions regarding…
Telix Pharmaceuticals (ASX:TLX): It’s made ~A$1.7bn in revenue from Illucix, but here’s why the best is yet to come!
What would you have thought if you were told 5 years ago you would see Telix Pharmaceuticals as a successful…
Anti Woke ETFs: Do they practice what they preach and have they outperformed since Trump’s return to power?
Have you ever heard of so-called ‘Anti Woke ETFs’? If you’re sick of companies that are big on ESG, this…